'Thor­ough­ly f*****d' for cy­ber­at­tacks?; Bad week for drug de­vel­op­ers; The next big I/O break­through?; Bio­gen does a deal; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

If you no­ticed the ex­tra bulky Phar­ma sec­tion this week, that’s be­cause we’ve of­fi­cial­ly launched End­pointsPhar­ma — our dai­ly email re­port on all things phar­ma strat­e­gy, mar­ket­ing and com­mer­cial­iza­tion. If you like it, please do spread the word.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER